Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2024-07-10

Clinical Trial Update: A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease [Phase 2]

View source ↗

Summary

Telios Pharma is evaluating TL-925 ophthalmic emulsion for dry eye disease in a Phase 2 trial that is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TL-925 Ophthalmic Emulsion (TL-925 ophthalmic emulsion)

Snippet

Sponsor: Telios Pharma, Inc. | Conditions: Dry Eye Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING